



## Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

March 8, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- [Acumen Pharmaceuticals, Inc.](#) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET. The live webcast may be accessed under the Investors tab on [www.acumenpharm.com](http://www.acumenpharm.com) and will be archived for 14 days.

### **About Acumen Pharmaceuticals, Inc.**

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A $\beta$ Os) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on A $\beta$ Os, which a growing body of evidence indicates are primary triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble A $\beta$ Os in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit [www.acumenpharm.com](http://www.acumenpharm.com).

### **Investors:**

Alex Braun

[abraun@acumenpharm.com](mailto:abraun@acumenpharm.com)

### **Media:**

[AcumenPR@westwicke.com](mailto:AcumenPR@westwicke.com)